One mission.

Advancing an inspired pipeline of novel IL-1β pathway inhibitors focused on treating unmet medical needs.

Avalo announces positive topline data from LOTUS study in moderate to severe hidradenitis suppurativa (HS) Press release presentation

Avalo is a clinical-stage biotechnology company

dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS). We are pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb.

Developing novel therapeutics targeting the IL-1β pathway

Discover our innovative approach to next-generation treatments for inflammation.

Learn more

Our lead candidate, abdakibart (AVTX-009), recently completed Phase 2 clinical development

Explore how abdakibart (AVTX-009) could potentially transform the treatment of HS and other inflammatory diseases.

Learn more

Avalo is also advancing a long-acting next-generation anti-IL-1β monoclonal antibody (AVTX-010)

Discover how AVTX-010 has the potential to extend dosing intervals and build upon the differentiated profile established by abdakibart

Learn more

Join the passionate team at Avalo

Learn what makes us an inspiring and rewarding place to build your career.

Learn more